Magazine
Issue 4-2015
Guest Editorial: Letter from the president, European AIDS Clinical Society
Manuel Battegay
EACS Guidelines 8.0: the big reduction
José R Arribas
Lighter Antiretroviral Therapy: what ’s new from european teams?
Christine Katlama
HIV and Hepatitis Nordic Conference 2015
Per Lundblad
Satellite Symposiums at the HIV and Hepatitis Nordic Conference
Per Lundblad
Doctor, I can’t sleep!
Graeme Moyle
Notes 2015
Leo Flamholc
Issue 3-2015
Letter from the Editor
Magnus Gisslén
The 7th Gilead Nordic Summer HIV Meeting
Eva Nordin
Three clinical trials of antiretroviral therapy at IAS 2015
José Arribas
Now is the time to start
Graeme Moyle
Risk for hepatocellular cancer in patients with cured hepatitis C
Soo Aleman
When to start? The end of an endless question
Christine Katlama
Notes 2015
Leo Flamholc
Issue 2-2015
Letter from the Editor
Magnus Gisslén
ILC in Vienna
Per Lundblad
Efavirenz: too much of a good thing?
Jose R Arribas
The new DHHS guidelines. Forgetting evidence, embracing opinion
Graeme Moyle
Topical Conferences
New drugs from new classes of drugs
Christine Katlama
Monitoring the persistent HIV reservoir in the era of HIV cure trials
Ward de Spiegelaere and Linos Vanderkerckhove
Symposium on the search for a cure
Per Lundblad
Banishing B - going beyond management
Per Lundblad
Conquering C - going beyond cure
Per Lundblad
The new landscape in management of HCV
Per Lundblad
Notes 2015
Leo Flamholc
Issue 1-2015
Letter from the Editor
Magnus Gisslén
CROI 2015
Per Lundblad
Hepatitis C Price war begins
Graeme Moyle
In search for better nucleos(t)ides. Is TAF the answer?
Jose Arribas
Smoking shortens life more than HIV, Hepatitis C. Varenecline may help stop
Graeme Moyle
What´s new in prevention?
Christine Katlama
Partnering for cure meeting in Stockholm
Per Lundblad
Seven novel HCV DAAs approved - confused by too many options?
Heiner Wedemeyer
Notes 2015
Leo Flamholc
Topical Conferences
Issue 4-2014
Letter from the Editor
Magnus Gisslén
HIV Drug Therapy Congress Glasgow 2014
Per Lundblad
Where now for Protease inhibitors?
Graeme Moyle
PROTEA: the end of the road of protease inhibitor monotherapy?
José R Arribas
HIV News from Glasgow 2014
Christine Katlama
HIV Nordic Conference Stockholm 2014
Per Lundblad
Satellite Symposiums at the HIV Nordic Conference
Per Lundblad
AASLD 2014: the era of IFN-free hepatitis C treatment is entering clinical practice!
Heiner Wedemeyer
Issue 3-2014
Letter from the Editor
Magnus Gisslén
6th Gilead Nordic Summer HIV Meeting
Per Lundblad
Nucleoside Free Zones
Graeme Moyle
SALT & OLE: ”If you can beat them, join them” (but just one of them)
José R Arribas
The 4th European Workshop on HIV Infection in the CNS (HANSA)
Aylin Yilmaz
The HCV drug-rally is ongoing: Simeprevir and Daclatasvir approved by EMA!
Heiner Wedemeyer
News from the Summer/Winter World AIDS Conference, Melbourne
Christine Katlama
Issue 2-2014
Letter from the Editor
Magnus Gisslén
Hepatitis treatment at the ILC in London
Per Lundblad
HHS Guidelines Update: What you shouldn´t miss
José R. Arribas
Tubular alarm bells
Graeme Moyle
News from CROI & EASL on Treatment of Hepatitis C in patients with HIV
Jürgen Kurt Rockstroh
EASL 2014: The ”100 %” Melting!
The NEJM: The Hepatitis C Journal!
Heiner Wedemeyer
Integrase Inhibitors in Clinical Practice: Today and Tomorrow
Christine Katlama
Issue 1-2014
Issue 4-2013
HIV treatment guidelines
Magnus Gisslén
14th EACS Conference in Brussels
Per Lundblad
14th European AIDS Conference: Update on ART
José Arribas
HIV-associated lymphoma: Treatment update
Hans Hagberg
AIDS Vaccine Congress in Barcelona
Per Lundblad
The price of antiretroviral therapy
Graeme J. Moyle
HIV & Hepatitis News
Leo Flamholc
New ARV drugs: What’s in the pipeline?
Christine Katlama
The path towards IFN-free therapy of hepatitis C
Part 4: We made it! IFN-free therapy is reality!
Heiner Wedemeyer
Topical Conferences in 2014
Issue 3-2013
Cure for hepatitis C achieved, but what about HIV?
Magnus Gisslén
The 5th Nordic Summer HIV Meeting
Per Lundblad
Women and Children last. Is drug development leaving the most in need behind?
Graeme J. Moyle
HIV & Hepatitis News
Leo Flamholc
ART and Cure – The post treatment controllers
Christine Katlama
The path towards IFN-free therapy of hepatitis C
Part 3: We need to be prepared
How to ensure access to novel antiviral therapies against hepatitis C?
Heiner Wedemeyer
SECOND-LINE & EARNEST
Nucleosides strike back
José Arribas
